Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis

Status:
Terminated

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

The objective of this study is to demonstrate that rPAF-AH is safe and reduces 28 day all cause mortality in patients with severe sepsis.

Phase 3

ICOS Corporation

Suntory Pharmaceutical